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Using mixed-methods, we investigated the CDF in the South West of England (3193 cancer patients
treated through the CDF, April 1st 2011–March 31st 2013) for evidence of: (1) equitable access across
socioeconomic groups, age groups, sex, and Cancer Network; (2) time-to-treatment by socioeconomic
group; and (3) the perception of the CDF as fair, using semi-structured interviews with oncology consul-
tants.
There was no evidence of inequitable access to anti-cancer therapy for those in more deprived areas.
For all cancer types, therewas a lower proportion ofwomen in the CDF cohort than in the Cancer Registry
reference population (e.g., melanoma, CDF 36.8% female, reference population 48.7%; difference 11.9%,
95% CI 3.1–20.7%). Therewas a lower proportion of older patients in the CDF comparedwith the reference
population (e.g., colorectal cancer, CDF 6.9%≥80 years, reference population 30.1%; difference 23.2%, 95%ealth services research CI 20.2–26.2%). Interviewedoncologists felt differences in performance status, not age, inﬂuenced referral
to the CDF, with neither deprivation, nor gender contributing.
Our study suggests that the CDF has differential access by age and sex, but not by deprivation. The
absence of high quality CDF data represents a missed opportunity to fully evaluate equity of access and
the real-world costs and outcomes of novel anti-cancer drugs.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND. Introduction
In 2011, the UK government introduced a £200 million Cancer
rugs Fund (CDF) to improve access to cancer drugs in England [1].
he CDF allowed access to: (a) drugswhichwere not recommended
y the National Institute for Health and Care Excellence (NICE)
ecause of poor or unproven cost-effectiveness; (b) drugs which
ad not yet been appraised by NICE; and (c) drugs used outside
heir marketing authorisation (off-label). In 2013, funding for the
DF was increased to £280 million annually and in 2014, a further
udget increase (to £340 million) was coupled with the introduc-
ion of cost-effectiveness as a criteria for drug availability on the
DF. This was primarily due to a CDF overspend (£30.5 million in
014) [2], but also reﬂects the rising number of high-cost cancer
rugs, increasing cancer incidence [3], and the absence of a plan to
isinvest from existing drugs to make way for new therapies. The
pportunity cost of the CDF has been the subject of intense debate,
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/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
for example, about whether the money could be better spent on
other cancer treatment modalities and/or other diseases [4].
Inequity of access to anti-cancer therapy in the UK, prior to the
CDF, has been demonstrated by: age [5,6]; deprivation [7–9]; place
of residence [10]; hospital involvement with clinical trials [11],
and hospital processes for facilitating best patient care (such as
Multi-Disciplinary Teammeetings) [12]. The intent of the CDF is to
provide all patients with better access to “cancer drugs their doc-
tors think will help them” [1]. However, there is no peer-reviewed
evidence on whether the CDF has reduced or exacerbated inequal-
ities in access to anti-cancer therapy. Using mixed-methods, we
assessed the strengths and weaknesses of the CDF for research
and investigated (1) whether access to the CDF during 2011–2013
was distributed equally across socioeconomic groups, age groups,
sex, and Cancer Network; (2) whether time to treatment on the
CDF varied by socioeconomic group; and (3) whether the CDF was
perceived by oncologists as being fair.under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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. Methods
.1. CDF cohort
Anonymised patient-level CDF data for the period April 1st
011–31st March 2013 for the south west (SW) region of England
ere obtained from NHS England South including age, sex, can-
er type, cancer drug, general practitioner (GP) postcode, referring
ospital trust, CancerNetwork, CDF panel decision, treatment start,
nd end date and date of death. Cancer Networks (CN) were con-
ederations of health organisations responsible for delivering the
ational Cancer Plan [13] in designated areas (now Strategic Clin-
cal Networks (2013)) [14]. Data were not available after March
1st 2013 because regional CDF arrangements were transferred
o a National Cohort List (a centrally agreed list of drugs avail-
ble across England through theCDF).Out-of-region applications to
he CDF (i.e., applications received in error and referred to another
egional CDF) were excluded from the analysis, as were applica-
ions during the interim CDF period (October 1st 2010–March 31st
011). Applications to the CDF which were not approved (3.0%)
ere not included in the analysis. Individuals who applied to the
DF more than once were identiﬁed by initials, GP postcode, diag-
osis and age, and only the ﬁrst application (93.8% of applications)
as included in the analysis. Our primary analysis included SW
atients resident in all six CNs (Avon Somerset and Wiltshire Can-
er Services (ASWCS), Dorset, Peninsula, 3 Counties, Central South
oast, andThamesValley)whichwerepartiallyorwholly contained
ithin the SW region. GP postcode data for all CDF participants
individual patient postcode data were not provided) were linked
o lower super-output areas (LSOA) to obtain National Index of
ultiple Deprivation (IMD 2010) quintiles [15]. Participants were
rouped into nine diagnosis categories based on the cancer name
ecorded on the CDF application. International Classiﬁcation of Dis-
ases (ICD-10) diagnosis codes were very poorly recorded (49.0%
issing or coded ‘N/A’) in the CDF. The diagnosis categories were:
olorectal; prostate; breast; malignant melanoma; lung; gynae-
ological; upper gastro-intestinal; haematological; and other rare
ancers. ‘Gynaecological cancer’ included uterine, ovarian and cer-
ical; upper GI cancer included gastric, hepatic, pancreatic, and
uodenal; and haematological cancer was made up of 84 differ-
nt categories, including pre-cancerous conditions ofmyeloﬁbrosis
nd amyloid. Other rare cancers were categorised based on being
member of the rare cancers list [16] and not being included in
ther named categories. Ethical approval was granted by the SW
EC (REC reference 13/SW/0007 January 2013).
.2. Cancer registry ‘reference’
We used cancer registry (CR) data to identify a comparative
roup of patients with advanced cancer in the SW regionwhowere
otentially eligible for CDF drugs (the ‘reference population’). The
R data, which includes information on cancer type, cancer stage,
ge, sex, and CN, were obtained from the public health England
PHE) Knowledge and Intelligence Team (SW). In our primary anal-
sis of seven of the nine cancer types, CR patients were included in
he reference population if they had the same cancer type,matched
o theappropriate ICD-10code, (Supplementarymaterial) andwere
advanced’ stage (IV). We selected only advanced stage tumors
s this represents the subgroup of cancer patients most likely to
e eligible for drugs prescribed on the CDF. In sensitivity analy-
is we expanded our inclusion criteria to include all stages. For
alignant melanoma, where Tumour-Node-Metastases, based on
reslowstaging,maybeusedmore commonly clinically, andwhere
tage IV cancers in the CR number less than those treated in the
DF, the reference population in the primary analysis included
all’ melanomas. For haematological cancers, where there is littleancer Policy 5 (2015) 25–30
stage 0–IV information in the CR, ‘all’ haematological cancers were
included in the reference population in the primary analysis. CR
patients’ postcodes were linked to IMD quintiles via LSOA.
2.3. Statistical analysis
2.3.1. Equity of access
Of 3530 CDF applications, 8 were out-of-region residents, 234
repeat applications for the same patient and 95 were not autho-
rised by the CDF panel and were excluded from analysis, leaving
3193 (Fig. 1). Of these, 367 (11.5%) had missing or incomplete GP
postcodes and could not be assigned an IMD designation. Other
patient characteristics were missing in ≤2% of CDF applications.
Chi-Squared, Ordinal Chi-squared, and Fisher’s Exact tests were
used to compare demographic characteristics of those treated on
the CDF with the reference population.
2.3.2. Time-to-treatment
Time to receipt of treatment was calculated from the date of
CDF panel authorisation to the date of treatment. Treatment start
date was missing or incomplete for 1330 (41.7%) patients. Due to
the large proportion ofmissing data, data were explored and found
to be ‘missing at random’ for all observed variables apart from CN.
A further 348 patients were excluded due to dates of authorisa-
tion occurring after treatment had started. Cancer typeswith fewer
than 100 subjects were excluded from the regression analysis. The
ﬁnal model excluded missing data in IMD (n=222) age (n=22),
and sex (n=5) resulting in a ﬁnal time-to-treatment analysis of
899 patients. Cox regression was used to calculate multivariable
adjusted hazard ratios for time-to-treatment, where a hazard ratio
>1 indicates more prompt treatment. Potential confounders were
identiﬁed a priori and assessed for inclusion using likelihood ratio
tests to develop the ﬁnal model (adjusted for age, sex, cancer type,
CN) for the impact of deprivation on time-to-treatment. All statis-
tical analyses were performed with Stata 13.1 (StataCorp).
2.4. Sensitivity analysis
In the absence of a unique patient identiﬁer linking the CR to
the CDF, or complete diagnostic (ICD-10) coding in the CDF, two
sensitivity analyses were conducted to assess assumptions used in
selecting the ‘reference population’ in the CR. Firstly, we included
‘all stage’ cancers of the same cancer type in the reference popu-
lation to test the assumption that ‘all’ stages better reﬂected the
population who were eligible to apply for the CDF than advanced
CR cancers in the primary analysis. Secondly, the study population
was restricted to those treated in the three CNswhose entire popu-
lationwas eligible for the SWCDF (ASWCS, Dorset, Peninsula). This
addresses the possibility that equity of access to the SW CDF was
being distorted by including CNs where some residents get care
through other regional CDFs.
2.5. Interview study
As part of a wider qualitative study, all colorectal and urological
oncology consultants in four hospitals in the SW region were iden-
tiﬁed through hospital switchboards and websites and invited to
take part in semi-structured interviews. Thirteen email and postal
invitations were distributed and ten interviews were conducted
between April 1st and December 31st 2013. Interview topic guides
wereused and includedquestions about the criteria that inﬂuenced
the oncologists’ decision to refer a patient to the CDF, experiences
of the CDF and its perceived impact on patients. Analysis used
the technique of constant comparison to compare transcripts and
elicit key themes [17]. The researchwas conducted iteratively,with
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3,530 applicants to the CDF
Equity of access CDF analysis 
(Table 1) (3,193 analysed)
Excluded: missing IMD (367)
Equity of access IMD analysis 
(Tables 3&4) (2,826 analysed)
Excluded: missing/incomplete treatment start date, 
(1,315) treatment not started (95) or not within 
me scenario (eg panel authorised aer treatment 
start (347))
For ﬁnal model excluded:
missing IMD (222) , missing age(26) missing sex (5)
Excluded: 
cancers with less than 100 subjects (161) 
and those outside three CNs wholly in 
SW (206)
899 included in me to 
treatment analysis (Table 5) 
Applicaons sent erroneously 
for out of region residents 
(8 excluded)
Applicaon not authorised by 
CDF panel for treatment 
(95 excluded)
Repeat applicaons for the same 
individual (234 excluded)
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sFig. 1. Cancer Drugs F
he topic guide updated to focus on emergent themes. Recruit-
ent continued until data saturation was reached. For this paper,
nterview excerpts were selected to inform interpretation of the
uantitative data.
. Results
In the 3193 unique patients (Table 1) approved for CDF treat-
ent in the two year cohort period, there were 77 different cancer
rugs prescribed at 31 hospitals. Table 2 displays interviewed par-
icipant characteristics (n=10).
.1. Equity of access
.1.1. Age and sex
There were fewer than expected numbers of patients in the 80
ears andover age category in theCDF comparedwith the reference
opulation, most notably in colorectal cancer patients (6.9% in the
DF, 30.1% in the reference population, difference =23.2% (95% CI
0.2–26.2)) (Table 3, Supplementary Table 1). In all cancer types
tudied, there was a lower proportion of women in the CDF than inarticipant ﬂow chart.
the reference population. The difference was largest for melanoma
(CDF 36.8% female, reference population 48.7%; difference 11.9%
(95% CI 3.1–20.7%)).
Oncology consultant participants universally felt that chrono-
logical age was not a ‘discriminator’ for referral to the CDF but
that older patients may not be referred where their co-morbidities
prevented it.
“I think the age issue is driven by general performance
status. . .it’s a question of whether someone is ﬁt enough for
treatment...people who are elderly will have less access to the
drugs fund and that’s a reﬂection that they have other medical
problems. . .I don’t think we select against patients on the basis
of age” [Dr. A, colorectal oncologist].
3.2. Socioeconomic status
The evidence of an association between socioeconomic status
and inclusion in the CDF was inconsistent between cancer types.
Prostate cancer and melanoma had greater proportions of indi-
viduals in more deprived areas (IMD quintiles 1–2) in the CDF,
compared with the expected proportion based on the reference
28 C. Chamberlain et al. / Journal of C
Table 1
Baseline characteristics of the CDF cohort.
Age (years) 0–59 800 (25.1%)
60–69 972 (30.4%)
70–79 963 (30.2%)
≥80 397 (12.4%)
Missing 61 (1.9%)
Diagnosis category Haematological (and amyloid) 808 (25.3%)
Colorectal 650 (20.4%)
Prostate 529 (16.6%)
Breast 389 (12.2%)
Other rare cancers 350 (11.0%)
Upper GI 136 (4.3%)
Skin 129 (4.0%)
Gynaecological 106 (3.3%)
Lung 87 (2.7%)
Unknown 4 (<1%)
Missing 4 (<1%)
Gender Male 1890 (59.2%)
Female 1282 (40.2%)
Missing 21 (<1%)
IMD quintile (2010) 1 (Most deprived) 266 (8.3%)
2 632 (19.8%)
3 758 (23.7%)
4 641 (20.1%)
5 (Least deprived) 529 (16.6%)
Missing 367 (11.5%)
Table 2
Interview participants.
Participant
(n=10)
Speciality Years a
consultant
> or ≤10 years
Sex Employment
setting
Dr. M OncColo ≤ F DGH
Dr. H OncColo ≤ F DGH
Dr. Y OncColo > M DGH
Dr. X OncColo > F DGH
Dr. A OncColo > M TH
Dr. C OncColo > F TH
Dr. D OncUrol > M TH
Dr. B OncUrol ≤ F TH
Dr. I OncUrol ≤ F DGH
Dr. G OncUrol > F DGH
Abbreviations: DGH—district general hospital, TH—teaching hospital, OncoUrol—
o
t
p
l
S
s
T
T
Hncology consultant specialising in urological disease; OncColo—oncology consul-
ant specialising in colorectal disease.
opulation: e.g., prostate cancer 31.8% CDF, 25.2% reference popu-
ation, quintile 1&2 ([difference =6.6% (95%CI 1.7–11.5%)]) (Table 3,
upplementary Table 1).
All but one interviewed oncologist dismissed the idea that
ocioeconomic status might inﬂuence referral patterns. One inter-
able 3
he Population of the CDF compared with the reference population for the CDF in the CR:
Haem CDF (%) Haem CRa (%) CRCCDF (%) CRC
Age (years) 0–59 143 (18.2) 513 (18.8) 203 (31.5) 287
60–69 219 (27.9) 614 (22.5) 229 (35.4) 372
70–79 273 (34.8) 776 (28.5) 171 (26.2) 464
≥80 150 (19.1) 823 (30.2) 45 (6.9) 483
X2 trend p value <0.001 <0.001 0.027 <0.0
Sex M 508 (63.3) 1544 (56.5) 388 (59.9) 869
F 294 (36.7) 1182 (43.3) 260 (40.1) 737
X2 p value 0.001 0.013 – –
IMD (2010)1 (most deprived) 64 (9.2) 174 (6.4) 46 (7.8) 121
2 158 (22.8) 480 (17.6) 144 (24.3) 304
3 162 (23.4) 758 (27.8) 164 (27.7) 417
4 164 (23.7) 815 (30.0) 132 (22.3) 462
5 (least deprived) 145 (20.9) 499 (18.3) 107 (18.0) 302
X2 trend p value 0.018 0.016 0.001 0.72
aem: Haematological CRC: Colorectal cancer.
a Denotes where ‘all’ stage of cancers are presented in place of stage IV cancers.ancer Policy 5 (2015) 25–30
viewed oncologist felt that a possible exception may be when a
complex explanation of the risks and beneﬁts of a treatment was
required (in this context an off-label drug on the CDF). In this
instance, deprivation may inﬂuence the likelihood of referral if an
alternative treatment could be chosen that required less explana-
tion.
“I suppose the only question about deprivation is would the
patient understand side effects and when to get help, so that
might sway you a little bit [not to refer to the CDF].” [Dr. X,
colorectal oncologist].
3.3. Cancer network
Use of the CDF by different CNs varied by cancer type (Table 4,
Supplementary Table 2). Variation between CNs was most evident
for colorectal and gynaecological cancers. For example, patients
residing in ASWCSmade up a higher proportion of the CDF colorec-
tal cancer cohort (55.0%) than the colorectal reference population
(34.7%), but the opposite trendwas observed for the gynaecological
cancer CDF (22.0%) and reference population (43.2%). There was no
variation in referral to the CDF by CN for breast, upper gastroin-
testinal, melanoma, and other rare cancers.
Three oncologists described a sense that geographic variation
had increased during the regional CDF but decreased following the
introduction of the National Cohort List.
“. . .creating the regional Cancer Drugs Fund. . .reintroduce [d]
the postcode prescribing that we were trying to get rid of by
having NICE. . .it’s a huge waste of money. . .having it in four
places around the country just to create inequality. . .it’s been
made into a central panel which is better. . .but then why not
just make it part of NICE.” [Dr C, colorectal oncologist].
Sensitivity analyses showed no difference in the direction of
trends (Supplementary Tables 3 and 4).
3.4. Time-to-treatment
Time-to-treatment did not vary by IMD quintile or sex (Table 5).
Patients in the Dorset CN had a faster time-to-treatment (hazard
ratio) (HR) 1.25 (95% CI 1.04–1.50, P=0.019, median 9.9 days) com-
pared with ASWCS (reference group 1.0, median time 15.8 days).
4. DiscussionOur study suggests that receiving primary care from a deprived
area has not been associated with worse access to the CDF. The
majority of interviewed participants believed there would be no
Age, sex and socioeconomic status.
CR (%) Prostate CDF (%) Prostate CR (%) Breast CDF (%) Breast CR (%)
(17.9) 21 (4.1) 60 (5.2) 170 (44.6) 160 (29.0)
(23.2) 125 (24.7) 268 (23.4) 115 (30.2) 111 (20.1)
(28.9) 241 (47.5) 418 (36.5) 64 (16.8) 145 (26.3)
(30.1) 120 (23.7) 399 (34.9) 32 (8.4) 136 (24.6)
01
(54.1) 529 (100) 1000 (100) 0 (0) 4 (0.7)
(45.9) 0 (0) 0 (0) 386 (100) 548 (99.3)
(7.5) 48 (10.6) 83 (6.7) 24 (6.9) 37 (6.7)
(18.9) 96 (21.2) 229 (18.5) 77 (22.0) 120 (21.7)
(26.0) 131 (28.9) 337 (27.2) 99 (28.5) 139 (25.2)
(28.8) 114 (25.2) 371 (30.0) 79 (22.7) 159 (28.8)
(18.8) 64 (14.1) 218 (17.6) 68 (19.6) 97 (17.6)
5
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Table 4
Cancer network in the CDF and in the reference population.
Cancer
network
Haem
CDF (%)
Haem
CRa (%)
CRC
CDF (%)
CRC
CR (%)
Prostate
CDF (%)
Prostate
CR (%)
Breast
CDF (%)
Breast
CR (%)
ASWCSb 249 (37.5) 1015 (43.1) 286 (55.0) 557 (41.4) 184 (38.5) 376 (35.7) 158 (46.5) 189 (40.0)
Dorset 128(19.3) 432 (18.3) 70 (13.5) 243 (18.1) 62 (13.0) 190 (18.1) 64 (18.8) 94 (19.9)
Peninsula 287 (43.2) 909 (38.6) 164 (31.5) 545 (40.5) 232 (48.5) 486 (46.2) 118 (34.7) 189 (40.0)
X2 p value 0.031 <0.001 0.044 0.172
a Denotes where ‘all’ stage of cancers are presented in place of stage IV cancers.
b Avon Somerset and Wiltshire Cancer Network.
Table 5
Timeliness of treatment on the CDF.
Time to treatment
n=899
HR (95% CI) HR
>1: faster time
to treatment
P-value
IMD 2010 National Quintile 1(most) 1.0 –
2 0.96 (0.75–1.24) 0.779
3 0.84 (0.66–1.08) 0.173
4 1.00 (0.78–1.29) 0.983
5 (least) 0.83 (0.63–1.09) 0.178
Test for trend 0.300
Age 0–59 1.0 –
60–69 1.00 (0.83–1.20) 0.986
70–79 0.95 (0.79–1.16) 0.637
≥80 0.95 (0.75–1.20) 0.663
Test for trend 0.569
Gender M 0.94 (0.79–1.11) 0.460
F 1.0 –
Cancer network ASWCS 1.0 –
Dorset 1.25 (1.04–1.50) 0.019
Peninsula 1.03 (0.88–1.20) 0.722
Cancer type Haematological 1.0 –
Colorectal 1.00 (0.82–1.22) 0.984
Prostate 0.98 (0.80–1.20) 0.857
a
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wBreast 1.05 (0.81–1.36) 0.702
Other rare 1.34 (1.06–1.71) 0.062
ssociation between CDF referral and patient deprivation. Prostate
nd melanoma cancer patients, who received their primary care in
ore deprived areas, were marginally more likely to be treated
n the CDF. The willingness of clinicians to provide the most
nnovative treatment for those presenting with advanced disease
where advanced presentation ismore likely in themore deprived)
18], combined with the tolerability of some newer cancer agents
e.g., Abiraterone) may explain this unexpected ﬁnding in the CDF.
rior to the CDF, increasing deprivation had been associated with
educed access to anti-cancer therapy in the literature [7–9].
Whether the preponderance of younger patients on the CDF is a
onsequence of better performance status (ﬁtness for anti-cancer
herapy), younger patients’ preference for more aggressive ther-
py or clinician preconceptions and inequities of referral, cannot
e determined without information on patients’ performance sta-
us. Interviewed oncologists felt poor performance status, not older
ge was the key barrier for referral to the CDF. The literature cor-
oborates older age as a barrier to anti-cancer therapy, even after
djustment for performance status [5,19].
The differential in CDF referral by gender is conceivably due
o poorer performance status at presentation among females. The
iterature on equity of access to anti-cancer therapy by gender is
imited, but a Canadian study found greater access to anti-cancer
herapy for men [20]. Potential explanations could include, prefer-
nce sensitive care [21], where gender treatment choices exclude
ystemic anti-cancer therapy or inadequate access due to com-
eting family commitments. No literature was identiﬁed which
orroborated these hypotheses.
Differences between CNs demonstrates a continuing ‘post-
ode’ lottery, which is in keeping with the clinician participant’s
ider concerns about geographical inequalities resulting from theregional CDF. There is also substantial evidence for variable access
to anti-cancer therapies by healthcare jurisdiction prior to the CDF
in the literature [22–25].
4.1. Strengths and limitations
Comparing the CDF population with a reference population
gives conservative results because the numerator (CDF partici-
pants), is also included within the denominator (CR reference
population), thereby attenuating differences between the two
groups. Deprivation in the CRdatawas estimated from the patient’s
residential postcodewhereas in the CDF, GP postcodewas used as a
proxy. As GP populations residewithin local boundary areas, we do
not believe this will have an important inﬂuence on our ﬁndings.
Imperfect matching between CDF and reference populations for
‘advanced’ cancer stagemay introduce selectionbias if CDFpatients
have more advanced disease than reference populations.
4.2. Implications
Our analysis of equity of access to the CDF is restricted by the
absence of key clinical variables (e.g., performance status) and
incomplete data, (e.g., >40% in treatment start date) which would
be required to more fully measure equity and assess survival. The
paucity of these prospectively collected data, which also excluded
quality of life, adverse event, and other core outcome data is inde-
fensible, as recognised in the House of Commons Committee of
Public Accounts (2015) [26]. If data quality cannot be improved,
future research should rely on linkage with reliable data sources
(e.g., CR, Hospital Episode Statistics) to overcome some limitations
of existing data, and adjust for co-morbidity as a proxy for perfor-
mance status. Given the huge amounts invested in the CDF, these
data are a missed opportunity for research.
5. Conclusion
Our study foundno increase in inequity of access to these agents
by socioeconomic status. Age and sex differences in access may
reﬂect unmeasured differences in patients’ performance status,
patient preferences, or inequity resulting from clinician pre-
conceptions about ﬁtness for therapy and patient wishes. Data
incompleteness and absent essential variables, such as perfor-
mance status, in the CDF data has made drawing ﬁrm conclusions
challenging. The CDF represents a missed opportunity for research
into the equity of access and real-world costs and outcomes of
anti-cancer therapies.
Conﬂict of interestsThis manuscript has been developed without conﬂict of inter-
ests from pharmaceutical companies or political bias. Public health
England (LH) is an executive agency, sponsored by the Department
of Health and is not constrained by government policy.
3 al of C
F
r
H
a
D
A
u
A
t
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
the review undertaken by the National Cancer Director. Crown Copyright:
Department of Health, 2004.
[26] Progress in improving cancer services and outcomes in England. vol.0 C. Chamberlain et al. / Journ
unding
This work was produced under the terms of the Doctoral
esearch training fellowship issued by the National Institute for
ealth Research (NIHR). The views expressed are those of the
uthors and not necessarily those of the NHS, the NIHR or the
epartment of Health.
cknowledgment
Thanks to Dr Nigel Acheson for assisting us in accessing and
nderstanding the CDF data.
ppendix A. Supplementary data
Supplementary data associatedwith this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.jcpo.2015.06.003
eferences
[1] Stanton M., The Cancer Drugs Fund: a consultation. In. Edited by Health Do,
vol. Gateway Reference 14909: Crown Copyright; 2010.
[2] Summary Financial Report 2013–14 Cancer Drugs Fund. In. Edited by England
N. http://www.england.nhs.uk/wp-content/uploads/2014/08/cdf-summ-ﬁn-
pos-13-14pdf; 2014.
[3] Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, Khayat D,
Boyle P, Autier P, Tannock IF, et al. Delivering affordable cancer care in
high-income countries. Lancet Oncol 2011;12(10):933–80.
[4] Thornton S. Return of the postcode lottery Cancer Drugs Fund is not a fair
allocation of NHS resources. British Medical Journal 2011;342.
[5] Bouchardy C, Rapiti E, Blagojevic S, Vlastos AT, Vlastos G. Older female cancer
patients: importance, causes, and consequences of undertreatment. J Clin
Oncol 2007;25(14):1858–69 [Review] [139 Refs.].
[6] Reducing cancer inequality: evidence, progress and making it happen,
National Cancer Action Team, Crown Copyright: Department of Health; 2010.
[7] Forrest LF, White M, Rubin G, Adams J. The role of patient, tumour and system
factors in socioeconomic inequalities in lung cancer treatment:
population-based study. Br J Cancer 2014;111(3):608–18.
[8] Forrest LF, Adams J, Wareham H, Rubin G, White M. Socioeconomic
inequalities in lung cancer treatment: systematic review and meta-analysis.
PLoS Med 2013;10(2):e1001376.
[9] Aarts MJ, Lemmens VEPP, Louwman MWJ, Kunst AE, Coebergh JWW.
Socioeconomic status and changing inequalities in colorectal cancer? A
review of the associations with risk, treatment and outcome. Eur J Cancer
2010;46(15):2681–95.ancer Policy 5 (2015) 25–30
10] Chamberlain C, Collin SM, Stephens P, Donovan J, Bahl A, Hollingworth W.
Does the Cancer Drugs Fund lead to faster uptake of cost-effective drugs? A
time-trend analysis comparing England and Wales. Br J Cancer 2014.
11] Rich AL, Tata LJ, Free CM, Stanley RA, Peake MD, Baldwin DR, Hubbard RB.
How do patient and hospital features inﬂuence outcomes in small-cell lung
cancer in England? Br J Cancer 2011;105(6):746–52.
12] Forrest LM, McMillan DC, McArdle CS, Dunlop DJ. An evaluation of the impact
of a multidisciplinary team, in a single centre, on treatment and survival in
patients with inoperable non-small-cell lung cancer. Br J Cancer
2005;93(9):977–8.
13] The NHS Cancer Plan: A Plan for Reform. Edited by Health Do: Crown
Copyright; 2000.
14] The way forward, strategic clinical networks, <http://www.england.nhs.uk/
wp-content/uploads/2012/07/way-forward-scn.pdf/>.
15] English indices of deprivation, 2010, <https://www.gov.uk/government/
statistics/english-indices-of-deprivation-2010/>.
16] Surveillance of rare cancers in Europe, <http://www.rarecare.eu/rarecancers/
rarecancers.asp/>.
17] Glaser Bas AL. Discovery of Grounded Theory. Mill Valley, CA: Sociological
Press; 1967.
18] Lyratzopoulos G, Abel GA, Brown CH, Rous BA, Vernon SA, Roland M,
Greenberg DC. Socio-demographic inequalities in stage of cancer diagnosis:
evidence from patients with female breast, lung, colon, rectal, prostate, renal,
bladder, melanoma, ovarian and endometrial cancer. Ann Oncol
2013;24(3):843–50.
19] Reducing cancer inequality: evidence, progress and making it happen. A
report by the National Cancer Equality Initiative. In. Edited by Health Do.
Cancer Policy Team, Wellington house, 133–155 Waterloo Rd, SE1 8UG:
Department of Health; 2010.
20] Maddison AR, Asada Y, Urquhart R, Johnston G, Burge F, Porter G. Inequity in
access to guideline-recommended colorectal cancer treatment in Nova Scotia,
Canada. Healthcare Policy 2012;8(2):71–87.
21] Birkmeyer JD, Reames BN, McCulloch P, Carr AJ, Campbell WB, Wennberg JE.
Understanding of regional variation in the use of surgery. Lancet
2013;382(9898):1121–9.
22] Tackling cancer inequalities- one year on. All party parliamentary group on
cancer.
23] Beckett P, Woolhouse I, Stanley R, Peake MD. Exploring variations in lung
cancer care across the UK— the ‘story so far’ for the National Lung Cancer
Audit. Clin Med 2012;12(1):14–8.
24] Patel N, Adatia R, Mellemgaard A, Jack R, Moller H. Variation in the use of
chemotherapy in lung cancer. Br J Cancer 2007;96(6):886–90.
25] Richards M., Variations in usage of cancer drugs approved by NICE Report ofForty-ﬁfth report of session 2014–15. London: The Stationery Ofﬁce Limited:
House of Commons Committee of Public Accounts, 2015.
